Exabis Library

So many 5-ASA trials, so many guidelines - but what is the best dose and route we should be prescribing? According to Dr. Brigida Barberio and colleagues, network meta-analysis supports many aspects of current international guidelines, but highlights a key role for higher doses of oral 5-ASA for induction of remission in more extensive disease.

1. Should the target be histology?
2. Basic histology and definitions
3 Standardization - scoring
4. Histological remission and response
5. Usefulness of histology
6. Possible solutions and improvements

This talk aims to help developers of clinical practice guidelines learn how to use the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to frame health care questions, select and rate the importance of outcomes, grade the quality of evidence, create Summary of Findings Tables, and move from evidence to making recommendations.

Educational Objectives:
1. To understand the way of dosing and administration of ustekinumab in UC
2. To understand dosing, efficacy, side-effects of Tofacitinib 
3. To be familiar with the sc administration of Vedolizumab
4. To be familiar with the sc Administration of infliximab

What is the optimal timing and methods for monitoring?

Educational objectives:
1. To understand the importance of disease monitoring in a treat-to-target strategy
2. To understand the difference between a treatment target and an instrument of tight disease control
3. To understand the need for a non invasive patient-friendly disease monitoring
4. To emphasize a proposal for a structured time-bound monitoring

 Disease monitoring is the corner-stone of a treat-to-target strategy. The definition of the treatment target is linked to our understanding of the disease process and the availability of markers to assess the disease process. Beside the target, we may define several steps to reach the target which are associated with specific tools and markers. Monitoring tools are not unique and must be articulated in a time-bound manner to allow an optimal disease control aiming at alleviating the symptoms and avoiding disease progression. In particular is a full endoscopic healing is currently the most widely accepted objective, intermediate steps may include symptomatic improvement and biomarkers improvement and normalization.

Up to 50% of Crohn’s patients develop intestinal strictures during their disease course. In general, predominant-inflammatory strictures are likely to benefit from anti-inflammatory medical therapy, whereas predominant-fibrotic strictures often require endoscopical/surgical approach. However, rarely is a stricture merely inflammatory or fibrotic; they are typically characterised by a mixture of inflammation, muscular hypertrophy, collagen disposition and fibrosis. Cross-sectional imaging techniques allow full-thickness evaluation of the bowel wall, of which IUS is non-invasive, cost-effective and can be used in the point-of-care setting, which makes is an attractive tool for monitoring.
The aim of the talk is to review the challenges of distinguishing inflammatory and non-inflammation strictures on conventional B-mode IUS and on advanced US modalities, such as CEUS and elastography.  

To understand imaging findigs of Fibrosis on cross sectional imaging with emphasis on MR-E 
To review litterature on MR-E and fibrosis
To have an overview over new imaging tools of Fibrosis (delayed enhancement, DWI, IVIM, Magnetization trasfert, Motility study).

Educational Objectives:
1. To appreciate the strong impact of the diet on gut microbial community structure and function
2. To understand the role of the diet in the pathogenesis of experimental gut inflammation
3. To review a role of the diet on the development and course of human inflammatory bowel diseases